Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Paclitaxel and Carboplatin in Neoadjuvant TNBC
NCT03735082Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Pathologic Complete Response Rate at 3 months and Incidence of Adverse Events. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03735082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735082.